Pharmaceuticals France

France Sarcopenia Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France Sarcopenia Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $85.8 Mn Placeholder estimate
Estimate 2025 $90.8 Mn 2.6% of the global market
Projected 2034 $150.8 Mn 66.1% Adds $60.0 Mn over 9 forecast years
CAGR 2025–2034 5.8% Faster than 34% of 180 Pharmaceuticals markets here
Key players 5
  • France is 2.64% of the global market.
  • In Europe, the largest is Germany at $113.3 Mn.
  • Fastest growing: Russia at 6.8% a year.
  • France ranks 3rd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$60.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Sarcopenia Treatment Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $85.8 Mn — —
2025 (base) $90.8 Mn +$5.0 Mn —
2026 (forecast) $96.0 Mn +$5.3 Mn +5.8%
2027 (forecast) $101.6 Mn +$5.6 Mn +11.9%
2028 (forecast) $107.5 Mn +$5.9 Mn +18.4%
2029 (forecast) $113.7 Mn +$6.2 Mn +25.3%
2030 (forecast) $120.3 Mn +$6.6 Mn +32.6%
2031 (forecast) $127.3 Mn +$7.0 Mn +40.3%
2032 (forecast) $134.7 Mn +$7.4 Mn +48.4%
2033 (forecast) $142.5 Mn +$7.8 Mn +57%
2034 (forecast) $150.8 Mn +$8.3 Mn +66.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France Sarcopenia Treatment Market Analysis at a glance
Market size, 2025$90.8 Mn placeholder estimate
Forecast, 2034$150.8 Mn placeholder estimate
Growth (CAGR), 2025–20345.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, product and end user (see all)
Key playersAbbott Laboratories, Nestle, Regeneron Pharmaceuticals, Scholar Rock, Biophytis (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
Active clinical trials25 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Sarcopenia Treatment Market Analysis Executive Summary

Sarcopenia treatment aims to slow or reverse age-related loss of muscle mass and strength with nutrition, exercise and new medicines.

Key segments of the sarcopenia Treatment market include treatment (Nutritional Supplements, Exercise Programs and Pharmacological Therapy) and product (Protein and Amino Acids, Vitamin D and Myostatin Inhibitors).

Bar chart: France Sarcopenia Treatment market size, 2024–2034, placeholder estimates. $85.8 Mn in 2024, $90.8 Mn in 2025 and $150.8 Mn in 2034, 5.8% CAGR.
France Sarcopenia Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Sarcopenia Treatment Market Dynamics

Market Growth Drivers

An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the sarcopenia Treatment market. Older adults and their families are spending more on staying active and independent.

Opportunity

Preventive care, personalised plans based on biomarkers and home-based services give the sarcopenia Treatment market room to grow, especially in fast-ageing countries in Asia and Europe.

Market Restraints

Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the sarcopenia Treatment market.

Competitive Landscape for Sarcopenia Treatment Market in France

The sarcopenia Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Sarcopenia Treatment Market in France

Sarcopenia Treatment in France: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2] ClinicalTrials.gov lists 25 studies on Sarcopenia Treatment that are recruiting, active or about to start in France.⁠[3] People aged 65 and over: 22.5% of people in 2025, the latest World Bank figure for France.⁠[4]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.

[4] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for sarcopenia Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Sarcopenia Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 16 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Sarcopenia Treatment in context

France compared

  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[1]
  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[2]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Sarcopenia Treatment market in France?
Placeholder estimate: about $90.8 Mn in 2025, rising to about $150.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Sarcopenia Treatment market in France growing?
Placeholder estimate: about 5.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Sarcopenia Treatment market report cover?
The report splits the market by treatment (Nutritional Supplements, Exercise Programs, Pharmacological Therapy, Hormone Therapy), product (Protein and Amino Acids, Vitamin D, Myostatin Inhibitors) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Sarcopenia Treatment market?
Key players include Abbott Laboratories, Nestle, Regeneron Pharmaceuticals, Scholar Rock and Biophytis.
What is driving the Sarcopenia Treatment market?
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the sarcopenia Treatment market. Older adults and their families are spending more on staying active and independent.
Who regulates Sarcopenia Treatment in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How many clinical trials on Sarcopenia Treatment are running in France?
25 studies are recruiting, active or about to start in France, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
What does World Bank report for France?
People aged 65 and over: 22.5% of people in 2025, the latest World Bank figure. Source: World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
How much research is published on Sarcopenia Treatment?
PubMed lists 63 papers on Sarcopenia Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on geriatric and nutrition

See the topic